S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
S&P 500   4,071.70
DOW   34,429.88
QQQ   292.55
Today Only: Get a 4K Camera Drone for Just $80
Why Your IRA Could Crash on January 16th? (Ad)
Pentagon debuts its new stealth bomber, the B-21 Raider
Prosecutor: Evidence shows Trump 'explicitly' OK'd tax fraud
Why Your IRA Could Crash on January 16th? (Ad)
Why CSL Ltd Stock Could Be Worth a Look
Group of Seven nations and Australia join EU in setting $60-per-barrel price cap on Russian oil
Why Your IRA Could Crash on January 16th? (Ad)
Closing prices for crude oil, gold and other commodities
EXPLAINER: What's the effect of Russian oil price cap, ban?
TSE:APS

Aptose Biosciences - APS Stock Forecast, Price & News

C$0.96
+0.06 (+6.67%)
(As of 12/2/2022 12:00 AM ET)
Add
Compare
Today's Range
C$0.90
▼
C$0.98
50-Day Range
C$0.63
▼
C$1.03
52-Week Range
C$0.62
▼
C$2.72
Volume
44,801 shs
Average Volume
26,760 shs
Market Capitalization
C$88.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
C$8.50

Aptose Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
785.4% Upside
C$8.50 Price Target
Short Interest
N/A
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
Acquiring Shares
C$5,025 Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.59 out of 5 stars

See Top Rated MarketRank™ Stocks Here
APS stock logo

About Aptose Biosciences (TSE:APS) Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc. to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was founded in 1986 and is headquartered in Mississauga, Canada.

Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Stock News Headlines

September 27, 2022 | finance.yahoo.com
Seagen (SGEN) Inks Deal With LAVA Therapeutics for LAVA-1223
September 13, 2022 | finance.yahoo.com
Aptose Strengthens Board of Directors with Appointment of Bernd R. Seizinger, M.D., Ph.D.
September 12, 2022 | benzinga.com
Aptose's New "G3" Formulation of Luxeptinib Boosts Bioavailability
July 23, 2022 | finance.yahoo.com
Is Aptose Biosciences (TSE:APS) In A Good Position To Invest In Growth?
July 19, 2022 | finance.yahoo.com
Aptose to Report Second Quarter 2022 Financial Results and Hold Conference Call on Tuesday, August 2, 2022
May 9, 2022 | finance.yahoo.com
Aptose Reports Results for the First Quarter 2022
May 4, 2022 | finance.yahoo.com
Aptose Receives Fast Track Designation for HM43239 in Relapsed/Refractory AML Patients and FLT3 Mutation
March 8, 2022 | finance.yahoo.com
Aptose to Report Fourth Quarter and Full Year 2021 Financial Results and Hold Conference Call on Tuesday, March 22, 2022
March 1, 2022 | finance.yahoo.com
Aptose to Present at Oppenheimer’s 32nd Annual Healthcare Conference
December 16, 2021 | msn.com
Aptose Biosciences Climbs 17% to Reclaim Some Losses
December 15, 2021 | finance.yahoo.com
Insiders who purchased this year lose US$89k as Aptose Biosciences Inc. (TSE:APS) stock drops to CA$1.44
December 13, 2021 | finance.yahoo.com
HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia
November 26, 2021 | finance.yahoo.com
Implied Volatility Surging for Aptose Biosciences (APTO) Stock Options
November 24, 2021 | finance.yahoo.com
Why Investors Should Hold on to Universal Health (UHS) Stock
November 22, 2021 | finance.yahoo.com
Aptose to Present at the Piper Sandler 33rd Annual Healthcare Conference
November 11, 2021 | finance.yahoo.com
Aptose Reports Results for the Third Quarter 2021
November 4, 2021 | finance.yahoo.com
Aptose Clinical Data to be Presented at the 2021 ASH Annual Meeting
August 19, 2021 | finance.yahoo.com
AzurRx (AZRX) Pancreatic Insufficiency Study Meets Endpoints
August 18, 2021 | finance.yahoo.com
Agios (AGIO) Rare Disease Drug NDA Gets FDA Priority Review
August 6, 2021 | finance.yahoo.com
Aptose Biosciences (APTO) Loses 19.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
August 3, 2021 | finance.yahoo.com
Aptose Reports Results for the Second Quarter 2021
August 2, 2021 | finance.yahoo.com
We Think Aptose Biosciences (TSE:APS) Can Afford To Drive Business Growth
July 26, 2021 | finance.yahoo.com
Were Hedge Funds Right About Cutera, Inc. (CUTR)?
July 20, 2021 | finance.yahoo.com
Aptose to Report Second Quarter 2021 Financial Results and Hold Conference Call on Tuesday, August 3, 2021
July 19, 2021 | finance.yahoo.com
Hedge Funds Are Crazy About Aptose Biosciences Inc (APTO)
See More Headlines
Receive APS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptose Biosciences and its competitors with MarketBeat's FREE daily newsletter.

APS Company Calendar

Today
12/03/2022
Next Earnings (Estimated)
3/28/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
TSE
Industry
Biotechnology
Sub-Industry
N/A
Sector
Medical
Current Symbol
TSE:APS
CUSIP
N/A
CIK
N/A
Web
aptose.com
Phone
+1-647-4799828
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
C$8.50
High Stock Price Forecast
C$12.00
Low Stock Price Forecast
C$5.00
Forecasted Upside/Downside
+785.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.58
Current Ratio
5.53
Quick Ratio
5.41

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
C$0.63 per share
Price / Cash Flow
1.53
Book Value
C$0.51 per share
Price / Book
1.89

Miscellaneous

Outstanding Shares
92,295,000
Free Float
N/A
Market Cap
C$88.60 million
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Dr. William G. Rice Ph.D. (Age 59)
    Chairman, Pres & CEO
  • Mr. Gregory K. Chow CPA (Age 45)
    MBA, BA, Sr. VP, CFO & Principal Accounting Officer
  • Mr. Ernest Kitt B.S.
    M.S, VP of Devel. & Technical Operations
  • Dr. Stephen B. Howell (Age 73)
    Chief Medical Officer
  • Mr. Peter Murray
    Director of Clinical Devel.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













APS Stock - Frequently Asked Questions

Should I buy or sell Aptose Biosciences stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aptose Biosciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" APS shares.
View APS analyst ratings or view top-rated stocks.

What is Aptose Biosciences' stock price forecast for 2023?

3 brokerages have issued 1 year price targets for Aptose Biosciences' shares. Their APS share price forecasts range from C$5.00 to C$12.00. On average, they expect the company's stock price to reach C$8.50 in the next twelve months. This suggests a possible upside of 785.4% from the stock's current price.
View analysts price targets for APS or view top-rated stocks among Wall Street analysts.

How have APS shares performed in 2022?

Aptose Biosciences' stock was trading at C$1.73 at the start of the year. Since then, APS stock has decreased by 44.5% and is now trading at C$0.96.
View the best growth stocks for 2022 here.

When is Aptose Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023.
View our APS earnings forecast.

What other stocks do shareholders of Aptose Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptose Biosciences investors own include Aptose Biosciences (APTO), Aurinia Pharmaceuticals (AUPH), Advanced Micro Devices (AMD), NVIDIA (NVDA), Aurora Cannabis (ACB), Adobe (ADBE), AltaGas (ALA), Aphria (APHA), Algonquin Power & Utilities (AQN) and Badger Daylighting (BAD).

What is Aptose Biosciences' stock symbol?

Aptose Biosciences trades on the Toronto Stock Exchange (TSX) under the ticker symbol "APS."

How do I buy shares of Aptose Biosciences?

Shares of APS stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is Aptose Biosciences' stock price today?

One share of APS stock can currently be purchased for approximately C$0.96.

How much money does Aptose Biosciences make?

Aptose Biosciences (TSE:APS) has a market capitalization of C$88.60 million.

How can I contact Aptose Biosciences?

Aptose Biosciences' mailing address is 5955 Airport Rd Suite 228, MISSISSAUGA, ON L4V 1R9, Canada. The official website for the company is aptose.com. The biotechnology company can be reached via phone at +1-647-4799828.

This page (TSE:APS) was last updated on 12/3/2022 by MarketBeat.com Staff